VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
VBIV was delisted on the 7th of August, 2024.
39 hedge funds and large institutions have $1.71M invested in VBI Vaccines, Inc. New Common Stock (Canada) in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 10 reducing their positions, and 4 closing their positions.
53,100% more call options, than puts
Call options by funds: $532K | Put options by funds: $1K
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
5% more funds holding
Funds holding: 37 → 39 (+2)
10% less capital invested
Capital invested by funds: $1.9M → $1.71M (-$193K)
50% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$72.2K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$43.6K |
| 3 |
Renaissance Technologies
New York
|
+$23.8K |
| 4 |
Goldman Sachs
New York
|
+$18.3K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$14.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$42.3K |
| 2 |
GAI
General American Investors
New York
|
-$41.7K |
| 3 |
Millennium Management
New York
|
-$29.7K |
| 4 |
HF
HRT Financial
New York
|
-$15K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$8.16K |
VBIV Hedge Fund Activity: Q4 2023 in Review
39 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) for Q4 2023, worth a combined $1.71M — down 10% from $1.9M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new VBIV positions and 4 closed out — a net gain of 2 holders — while 5 added to existing stakes and 10 trimmed.
The largest buyer was Vanguard Group, adding an estimated $72.2K. The largest seller was Alyeska Investment Group, cutting an estimated $42.3K.
- 39 institutional investors held VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) as of Q4 2023, up from 37 in Q3 2023.
- Funds reported $1.71M of VBI Vaccines, Inc. New Common Stock (Canada) stock for Q4 2023, down 10% quarter-over-quarter.
- 6 funds opened new VBI Vaccines, Inc. New Common Stock (Canada) positions in Q4 2023 and 4 closed out, a net change of +2 holders.
- The largest VBI Vaccines, Inc. New Common Stock (Canada) buyer in Q4 2023 was Vanguard Group, an estimated $72.2K added.
- The largest VBI Vaccines, Inc. New Common Stock (Canada) seller in Q4 2023 was Alyeska Investment Group, an estimated $42.3K sold.
Based on aggregated 13F filings for Q4 2023.